by Clinical Neuropsychologist Online | Friday, September 11, 2026 | Dementia
Abstract INTRODUCTION The cognitive implications of longitudinal frailty exposure remain unclear. We examined associations of baseline frailty status, two-wave frailty change, and mean frailty burden with annual cognitive change and cognitive aging trajectories....
by Clinical Neuropsychologist Online | Thursday, September 10, 2026 | Dementia
Abstract INTRODUCTION Co-pathologies – including Lewy body, vascular, and TDP-43 lesions – are common in Alzheimer’s disease (AD), contributing to its clinical and pathological heterogeneity. Genetic risk factors may drive mixed pathology presentation, but their...
by Clinical Neuropsychologist Online | Wednesday, September 9, 2026 | Dementia
Abstract INTRODUCTION Blood plasma biomarkers identifying Alzheimer’s disease (AD) neuropathology offer accessible and scalable alternatives to lumbar puncture and positron emission tomography (PET) scans, with potential efficiency gains in clinical trial...
by Clinical Neuropsychologist Online | Wednesday, September 9, 2026 | Dementia
Dementia, Ahead of Print. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | September 9, 2026 Neuro-Dementia Previous...
by Clinical Neuropsychologist Online | Wednesday, September 9, 2026 | Dementia
Abstract INTRODUCTION Adults with Down syndrome (DS) have a higher risk of Alzheimer’s disease (AD). As gut microbiota (GM) alterations have been reported in AD, we investigated their association with cognitive decline and plasma AD biomarkers in DS. METHODS...
